Navigation Links
Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Date:8/19/2007

WAYNE, N.J., Aug. 3 /PRNewswire/ -- Patients treated with Betaseron(R) (interferon beta-1b) shortly after their first clinical MS event or "attack" showed a 40 percent lower risk of developing confirmed disability progression compared to patients in whom treatment was delayed. The results-which were fast-tracked and published in The Lancet this week-provide the first controlled evidence that delaying Betaseron treatment has an effect on later accumulation of disability, as observed over the three-year study period. No other MS therapy has demonstrated this effect in this early patient population.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/bayer/29192/

The BENEFIT study (Betaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment. The study was conducted at 98 sites in 20 countries and included a total of 468 patients.

In the study, investigators measured progression of patient disability using a validated scale called EDSS (Expanded Disability Status Scale).(1) Disability progression was defined as an increase in a patient's EDSS score by at least one point that was confirmed after six months. A confirmed increase by one point in the EDSS scale can be an important and robust predictor of permanent and severe disability later in the disease.(2)

"This research has important implications for the way we treat MS because, for the first time, we have controlled data that irrefutably demonstrates the value of early intervention with effective treatment for patients," said Dr. Ludwig Kappos, Professor of Neurology and Clinical Neuroimmunology at the University of Basel, Switzerland and lead investigator of the BENEFIT study. "These findings support the decision to actively treat patients at the first clinical sig
'/>"/>

SOURCE Bayer

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
7. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... CHICAGO, Dec. 2 A stu...EM), a new technique for imaging the breast, is no...ormonal status, two factors that limit the effecti...g cancer. Results will be presented today at the a... America (RSNA). , , "The ability of PEM t...
(Date:12/1/2008)...1 S*BIO Pte Ltd today announced th...18, a potent and orally-active JAK2 inhibitor, in ...with chronic idiopathic myelofibrosis (CIMF). , ...ty and tolerability of SB1518 in patients with CIM... Phase 1 part of the study will assess the safety ...
(Date:12/1/2008)...hows the Prox1 gene is a two-way switch that, if t...e reprogrammed so that they lose their identity an..., MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/...spital have discovered that a certain differentiat...at it requires the constant expression of a gene c...
(Date:12/1/2008)...enmark, December 1 Follo...he intent to procure an MVA-based,third generati...ervices,Canada, on behalf of the Canadian Departm...o Bavarian Nordic for the delivery of IMVAMUNE(R)....MVAMUNE(R) as part of the,country,s bio-preparedn...
Breaking Medicine Technology:New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Streams natural filters if not overloaded 2489 1Streams natural filters if not overloaded 2489 2Hope In Action 3A Policymakers and Artists Promote Youth and Latino Suicide Prevention 14236 1Hope In Action 3A Policymakers and Artists Promote Youth and Latino Suicide Prevention 14236 2Hope In Action 3A Policymakers and Artists Promote Youth and Latino Suicide Prevention 14236 3Statement of Bernadette Toomey President and Chief Executive Officer American Lung Association 14232 1Statement of Bernadette Toomey President and Chief Executive Officer American Lung Association 14232 2Statement of Bernadette Toomey President and Chief Executive Officer American Lung Association 14232 3California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 14228 1California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 14228 2California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 14228 3California Study Offers New Perspective on Relationship Between Staffing Ratios and Patient Safety 14228 4
(Date:12/2/2008)...es that the SouthEast Alaska Regional Health Conso... Rhapsody™ Integration Engine to help the di...acy, laboratory and business programs communicate ...ity to statewide systems such as VacTrAK (the Stat...MIS and clinical documentation tool used by substa...
(Date:12/2/2008)...Population Services International (PSI) is launchi...ally reduce the number of African children dying e...ree artemisinin-based combination therapies (ACT) ...ildren suspected of having malaria. This quick-res...etermine if it reduces the number of African child...
(Date:12/1/2008)...Toy Puppies to the Obama Daughters , , WASH... been made of President-Elect Obama,s first promis...ughter,s asthma and allergies, and timing issues, .... So, in the meantime, the Asthma and Allergy Fou...mp; allergy friendly" toy puppies to the Obama chi...
(Date:12/1/2008)...tomography (CT) colonography, also known as virtua... diseases at oncecolorectal cancer and osteoporosi...0. Results of the study will be presented today at... North America (RSNA). , "With CT colonography, ... were able to identify patients with osteoporosis,...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...ain medications widely prescribed for rotator cuff...or cuff is composed of the muscles and tendons tha...it to the shoulder joint. The research involved 18...repair surgery. One-third of the rats were treated...
...antiretroviral therapy HAART, the cytomegalovirus ...ortunistic// infections that spread out of control...shorter time to death. Researchers assessed CMV s...HIV using a standard test. Investigators followed ...
...reened for cervical cancer, according to a new stu...routine // Pap smears are unnecessary for women wh...ancerous diseases. Since most of these women no lo...r cervical cancer. A survey done by researchers on...
...ption may be partly to blame for patients sufferin...ainly caused // by alcohol abuse and gall stones. ...nal pain, often accompanied by nausea and vomiting.... Researchers say pancreatitis has a poor prognosi...
Other Medicine News:
...The new Finnpipette Focus from Thermo Labsystems w...h uncompromising performance. Advanced features s...lume adjustment on microvolumes help to define thi...new interchangeable handle plate offers a custom f...
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference.
Designed to inform decision making, PatientKeeper's Clinical Results delivers complete patient data on demand. Clinicians can rely on immediate access to lab results, medication profiles, microbiolog
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff.
Medicine Products: